Share This Page
sulfacytine - Profile
✉ Email this page to a colleague
What are the generic sources for sulfacytine and what is the scope of patent protection?
Sulfacytine
is the generic ingredient in one branded drug marketed by Glenwood and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for sulfacytine
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for sulfacytine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenwood | RENOQUID | sulfacytine | TABLET;ORAL | 017569-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario, Market Dynamics, and Financial Trajectory for Sulfacytine
Summary
Sulfacytine, a sulfonamide antibiotic developed in the mid-20th century, remains relevant in specific antimicrobial niches. Despite newer agents, its historical presence and ongoing clinical use in some regions sustain a niche market. This report analyzes its current investment landscape, market dynamics, and potential financial trajectory, emphasizing strategic considerations for stakeholders.
Introduction to Sulfacytine
| Attribute | Details |
|---|---|
| Chemical Class | Sulfonamide antibiotic |
| Introduced | 1940s (first synthesized and marketed) |
| Primary Use | Treatment of bacterial infections, especially in resource-limited settings |
| Current Status | Limited use, regional availability, off-patent |
| Patent Status | Off-patent globally; no active patent rights remaining |
Historical and Current Market Context
Development Timeline
| Year | Milestone | Impact |
|---|---|---|
| 1940s | Discovery and initial approval | Wide adoption as an affordable antibiotic |
| 1960s | Introduction of newer sulfonamides and antibiotics | Market saturation, decline in sulfacytine use |
| 1980s-2000s | Reduced prescribing, regional uses | Niche, often in developing economies |
| 2020s | Continued regional use, off-patent generic availability | Limited growth, stable niche market |
Market Size and Regional Insights
| Region | Estimated Market Size (USD millions) | Notes |
|---|---|---|
| North America | $5-10 million | Minimal use; replaced by newer agents |
| Europe | $3-8 million | Limited prescription; off-label and niche uses |
| Asia-Pacific | $10-20 million | Moderate use, especially in resource-limited settings |
| Africa & Middle East | $8-15 million | Significant because of affordability and access constraints |
Market Drivers
| Driver | Description |
|---|---|
| Cost-effectiveness | Low-cost generic formulations dominate in emerging markets |
| Resistance profile | Resistance to other antibiotics sustains sulfacytine’s niche |
| Regional healthcare policies | Use in resource-limited health systems where alternatives are unavailable |
| Regulatory environments | Approvals vary; in some regions, off-label or unregulated use |
Market Dynamics and Competitive Landscape
Competitive Overview
| Competitor / Agent | Similarity / Distinction | Market Position |
|---|---|---|
| Sulfadiazine, sulfamethoxazole | Other sulfonamides with broader spectrum or better pharmacokinetics | More modern, preferred options |
| Trimethoprim-sulfamethoxazole | Synergistic combination, broader activity, more marketed | Dominates in multi-drug regimens |
| Newer antibiotics (e.g., cephalosporins, fluoroquinolones) | Superior pharmacology and resistance profiles | Superior, but more expensive |
Supply Chain and Manufacturing
| Aspect | Status |
|---|---|
| Production | Generic manufacturers dominate; de-listed from many brands |
| Pricing | Competitive, low-cost due to off-patent status |
| Regulatory Status | Approved in select regions; unregulated in others |
Regulatory and Policy Considerations
| Policy Element | Impact |
|---|---|
| WHO Essential Medicines List | Included in some editions, supporting continued use |
| Regional approvals | Varies; limited in some markets, more in developing regions |
| Resistance Monitoring | Rising concerns; may impact future use |
Financial Trajectory and Investment Outlook
Revenue Forecast (2023–2030)
| Scenario Type | Market Size (USD millions) | Growth Rate | Rationale |
|---|---|---|---|
| Conservative | $15–20 million | 0-2% | Limited expansion, demographic plateau |
| Moderate | $25–30 million | 2-5% | Slight resurgence in niche markets, supply stability |
| Optimistic | $35–50 million | 5-10% | Potential regional policy shifts or new indications |
Key Factors Affecting Trajectory
| Factor | Positive / Negative | Impact on Investment |
|---|---|---|
| Resistance trends | Negative | Decreased efficacy, market shrinkage |
| Regulatory policies | Mixed | Restricted use or expanded approvals |
| Market repurposing or new indications | Positive | Potential new revenue streams |
| Manufacturing costs | Stable / Decreasing | Maintains low-cost advantage |
Investment Opportunities
| Opportunity | Description | Risk Factors |
|---|---|---|
| Generic manufacturing | Focused production to meet regional demand | Market saturation, low margins |
| New indications research | Investigate local resistance profiles for repurposing | R&D costs, regulatory hurdles |
| Regional expansion strategies | Target emerging markets seeking affordable options | Political, regulatory risks |
Comparison with Other Antibiotics
| Antibiotic Class | Spectrum | Resistance Trends | Cost | Current Use |
|---|---|---|---|---|
| Sulfonamides | Broad, primarily bacterial | Rising in some areas | Very low | Niche, resource-limited, historical use |
| Fluoroquinolones | Broad, highly potent | Increasing resistance | Moderate to high | Widely used but facing restrictions |
| Beta-lactams (Cephalosporins) | Broad, varied | Resistance developing | Moderate to high | Mainstream healthcare use |
Regulatory and Policy Environment
| Region | Status of Sulfacytine Approvals | Regulatory Trends |
|---|---|---|
| WHO | Included in some essential medicines lists | Supports continued use in specific contexts |
| U.S. | No current approval; off-label in some uses | Market not active; regulatory constraints |
| European Union | Limited approval; largely phased out | Regulatory focus shifted to newer agents |
| Emerging Markets | Approved or unregulated; availability varies | Often unregulated, posing safety concerns |
Strategic Considerations for Investors
| Aspect | Recommendations |
|---|---|
| Market Positioning | Capitalize on regional affordability and resistance profiles |
| R&D Investment | Explore re-purposing or combination therapies for niche indications |
| Regulatory Strategy | Engage with local authorities; leverage WHO listings for market entry |
| Supply Chain | Optimize for low-cost manufacturing; ensure consistent quality |
| Competitive Edge | Emphasize low-cost, proven efficacy in underserved markets |
FAQs
1. Is sulfacytine a viable investment today?
While its use has declined globally, sulfacytine remains economically viable in emerging and resource-limited markets where affordability outweighs the need for newer, more expensive agents. Investment may be justified if focused on regional production, supply chain management, or niche indications.
2. What are the major risks associated with investing in sulfacytine?
The primary risks include rising resistance, regulatory restrictions, declining clinical relevance, and potential competition from newer antibiotics with better pharmacological profiles. Additionally, unregulated markets pose safety and quality concerns.
3. How does sulfacytine compare to other sulfonamides and antibiotics?
It offers lower-cost options but has a narrower spectrum and increased resistance risk compared to newer agents like sulfamethoxazole. Its pharmacokinetic and safety profiles are less optimal, limiting its broader application.
4. Are there emerging indications or formulations that could revitalize sulfacytine's market?
Research into combination therapies and local resistance pattern assessments could identify niche indications. However, such efforts require significant investment and regulatory approval, with uncertain returns.
5. How might global health policies affect sulfacytine’s market?
Inclusion in WHO essential medicines lists supports ongoing use in developing countries, but global policies favor newer, more effective agents, potentially leading to market decline unless specific local needs are recognized.
Key Takeaways
- Market Marginalization: Sulfacytine’s global market has contracted; reliance persists chiefly in resource-limited regions due to low cost and existing supply chains.
- Limited Growth Prospects: Growth is constrained by resistance development, regulatory shifts, and the preferential use of newer antibiotics.
- Niche Investment Opportunities: Opportunities exist in regional production, supply chain efficiencies, and research into new indications—though these are not without significant risks.
- Regulatory Landscape: Varies significantly; global policies increasingly favor newer agents, though WHO lists support continued use in specific settings.
- Strategic Focus: Investors should prioritize low-cost manufacturing, regional market expansion, and niche applications, while closely monitoring resistance and regulatory trends.
References
[1] World Health Organization. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee. WHO Technical Report Series, No. 994, 2019.
[2] U.S. Food and Drug Administration (FDA). Approved Drugs Database. 2022.
[3] European Medicines Agency (EMA). Medicine Overview: Sulfacytine. 2023.
[4] Market Research Future. Global Antibiotics Market Forecast to 2027. 2022.
[5] IMS Health. Global Antibiotic Sales and Market Share. 2021.
End of Report
More… ↓
